Skip to main content

Table 1 TCGA cohorts of EAC and GAC

From: The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis

  

EAC (n = 89)

GAC (n = 371)

  

n (%)

n (%)

Sex

 

Male

77 (86.5)

242 (65.2)

 

Female

12 (13.5)

129 (34.8)

Median age (range)

 

69 years (28–86 years)

67 years (30–90 years)

pT

 

pTx

15 (16.8)

4 (1.1)

 

pT0

1 (1.1)

0 (0.0)

 

pT1

23 (25.8)

16 (4.3)

 

pT2

11 (12.3)

80 (21.6)

 

pT3

38 (42.7)

174 (46.9)

 

pT4

1 (1.1)

97 (26.1)

pN

   
 

pNx

16 (18.0)

11 (3.0)

 

pN0

22 (24.7)

115 (31.0)

 

pN1 + 

51 (57.3)

245 (66.0)

M

 

Mx

32 (36.0)

5 (1.3)

 

M0

52 (58.4)

347 (93.5)

 

M1

5 (5.6)

19 (5.1)

TCGA molecular subtypea

 

NA

131 (35.3)

 

EBV

24 (6.5)

 

MSI-high

48 (12.9)

 

GS

48 (12.9)

 

CIN

120 (32.3)

CLDN6 expressionb

  
 

 > Best cutoff

14 (15.7)

68 (18.3)

 

 < Best cutoff

75 (84.3)

303 (81.7)

Her2/ERBB status

 

Amplified

47 (5.9)

 
 

Not amplified

518 (64.5)

 
 

NA

238 (29.6)

 
  1. CIN chromosome instability-associated GAC, CLDN6 claudin 6, EAC esophageal adenocarcinoma, EBV EBV-associated GAC, GAC gastric adenocarcinoma, GS Genomic stable GAC, M distant metastasis, median age median age at diagnosis, pT tumor stage, pN lymph node stage, MSI-high microsatellite-instable GAC, NA not available, TCGA The Cancer Genome Atlas
  2. aMolecular subtype according to the molecular TCGA subtype classification of GAC [29]
  3. bCLDN6 expression (TPM, RSEM-normalized) dichotomized by the best cutoff value for a significant difference in overall survival in a log-rank test (see methods)